EditorialA vial of the Pfizer-BioNTech Covid-19 bivalent booster at a pop-up vaccination event for seniors in Chicago, Sept. 13, 2022. (Jamie Kelter Davis/The New York Times)
EditorialMartin Kenyon, 91, outside Guy's Hospital in London, where he received a Pfizer-BioNTech COVID-19 vaccine, Dec. 8, 2020. (Mary Turner/The New York Times)
EditorialA vial containing the Pfizer-BioNTech coronavirus vaccine for children under five at a clinic in Hatfield, Pa. on June 30, 2022. (Hannah Beier/The New York Times)
EditorialPresident Joe Biden visits a COVID-19 vaccination clinic at the D.C. Health Center in Washington on Tuesday, June 21, 2022. (Haiyun Jiang/The New York Times)
EditorialVials of Pfizer-BioNTech COVID-19 vaccine at a mobile pediatric clinic in Miami, June 17, 2022. The CDC advisory panel raised concerns about the Pfizer-BioNTech vaccine bottles needing to have their labels updated to reflect new rules. (Saul Martinez/The New York Times)
EditorialA 5-year-old boy receives his first dose of a coronavirus vaccine at Texas Children’s Hospital in Houston on Nov. 3, 2021. (Meridith Kohut/The New York Times)
EditorialA woman receives her second Pfizer-BioNTech booster shot at a county health facility in San Jose, Calif., May 19, 2022. (Jim Wilson/The New York Times)
EditorialLiam King Koma Sillah, 7, is vaccinated against COVID-19 on Nov. 3, 2021, the first day that the vaccine became available for children ages 5-11, at Texas Children’s Hospital in Houston. (Meridith Kohut/The New York Times)
EditorialPresident Joe Biden receives his second COVID-19 booster shot at the White House in Washington on Wednesday, March 30, 2022. (Doug Mills/The New York Times)
EditorialA pharmacist prepares a COVID-19 booster shot at Meritus Medical Center in Hagerstown, Md., on Feb. 22, 2022. (Kenny Holston/The New York Times)
EditorialSyringes of the COVID-19 made by Pfizer/BioNTech vaccine for a vaccination site at a high school in Berkley, Mich., Jan. 20, 2021. (Emily Elconin/The New York Times)
EditorialA child prepares for a Pfizer-BioNTech COVID-19 vaccination in a van outside a school in Queens, Nov. 12, 2021. (James Estrin/The New York Times)
EditorialDeAnndra Domino, a phlebotomist, draws doses of the Pfizer-BioNTech COVID-19 vaccine at a community vaccination site in San Francisco, Aug. 1, 2021. (Mike Kai Chen/The New York Times)
EditorialA 14-year-old is inoculated with the Pfizer BioNTech coronavirus vaccine at a shopping center in San Antonio, Texas, May 13, 2021. (Tamir Kalifa/The New York Times)
EditorialResearchers have found that all four vaccines studied — Pfizer-BioNTech, Moderna, Johnson & Johnson and Novavax — produce T cells that retain much of their potency against the Omicron variant. (Kenny Holston/The New York Times)
EditorialFiona Backes, 5, sits with her mother after her first dose of the Pfizer-BioNTech coronavirus vaccine, at a high school gym in Southfield, Mich., Nov. 9, 2021. (Emily Elconin/The New York Times)
EditorialPaxton Bowers, 5, a leukemia patient at Texas Children’s Hospital in Houston, received a COVID-19 vaccine shot on Nov. 3, 2021. (Meridith Kohut/The New York Times)
EditorialMila Pagador, 5, speaks to registered nurse Ashley Bean before she receives her dose of the Pfizer-BioNTech COVID-19 vaccine in Albuquerque, N.M., Nov. 10, 2021. (Paul Ratje/The New York Times)